Genelux (GNLX) Long-Term Investments (2023 - 2024)

Genelux (GNLX) recorded quarterly Long-Term Investments of $1.0 million in Q3 2024, down 85.28% quarter-over-quarter from $6.8 million in Q2 2024.

Genelux (GNLX) Long-Term Investments (2023 - 2024) Analysis & Trends

Genelux's Long-Term Investments history runs 2 years deep, the most recent figure standing at $1.0 million for Q3 2024.

In Q3 2024, Long-Term Investments changed N/A year-over-year to $1.0 million; the TTM figure through Sep 2024 stood at $1.0 million (changed N/A YoY), while the FY2023 annual figure was $24000.0, changed N/A from the prior year.
Long-Term Investments was $1.0 million for Q3 2024 at Genelux, down from $6.8 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $6.8 million in Q2 2024 to a low of $24000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	5.17 Mn
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	5.75 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Genelux	129.36 Mn	129.36 Mn	-	-

Download Data